|
As the architect of a number of the pharmaceutical industry’s largest and most visible deals, Alan Biloski brings a wealth of experience to the GNS Board. During his three-year tenure at Merrill Lynch from 1998 to 2001, Dr. Biloski advised clients in approximately $100 billion of M&A transactions including Pfizer’s unsolicited bid for Warner Lambert, MedImmune’s acquisition of US Bioscience, and the sale of Mycogen to Dow Chemical. He counseled Immunex on the largest biotech equity offering in history. Previously, Dr. Biloski founded the Healthcare Group at Wasserstein Perella & Co. where he managed SmithKline Beecham’s acquisition of Sterling Winthrop (the biggest OTC deal ever) and the sale of Sterling Winthrop North American to Bayer. The former head of the Healthcare Mergers and Acquisitions Group at First Boston, Dr. Biloski also has experience as a venture capitalist with Johnston Associates, and as a strategic planner with Merck Sharp and Dohme Research Laboratories. He holds a Ph.D. in organic chemistry from Cornell University, an M.B.A. from Columbia University, and a B.S./M.S. in chemistry from Yale University. He is a visiting professor of finance at Cornell University’s Johnson Graduate School of Management. | 